Hepatitis B virus reactivation with a rituximab-containing regimen

• 作 者: Yutaka Tsutsumi Yoshiya Yamamoto Shinichi Ito Hiroyuki Ohigashi Souichi Shiratori Hirohito Naruse Takanori Teshima
• 机 构: Department of Hematology, Hakodate Municipal Hospital,Department of Gastro-enterology, Hakodate Muni
• 出 处: World Journal of Hepatology
• 发表日期: 2015年21期
• 关键词: autoimmune nucleoside rejection transplant regimen analogs currently graft admin

Rituximab is currently used not only in the treatment of B-cell lymphoma but also for various other diseases, including autoimmune diseases, post-transplant graft vs host disease, and rejection following kidney transplants. Due to rituximab’s widespread use, great progress has been made regarding research into complications that arise from its use, one of the most serious being the reactivation of hepatitis B virus(HBV), and efforts continue to establish guidelines for preventive treatment against this occurrence. This report discusses preventive measures against rituximab-induced HBV reactivation and future objectives.

Rituximab is currently not not only in the treatment of B-cell lymphoma but also for other diseases, including autoimmune diseases, post-transplant graft vs host disease, and rejection following kidney transplants. Due to rituximab’s widespread use, great progress has been made regarding research into complications that arise from its use, one of the most serious being the reactivation of hepatitis B virus (HBV), and efforts continue to establish directives for preventive treatment against this occurrence. This report a precept for preventive measures against rituximab-induced HBV reactivation and future objectives.